PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer

Autor: Chibaudel, Benoist, Maindrault-Goebel, Frédérique, Bachet, Jean-Baptiste, Louvet, Christophe, Khalil, Ahmed, Dupuis, Olivier, Hammel, Pascal, Garcia, Marie-Line, Bennamoun, Mostefa, Brusquant, David, Tournigand, Christophe, André, Thierry, Arbaud, Claire, Larsen, Annette K, Wang, Yi-Wen, Yeh, C. Grace, Bonnetain, Franck, de Gramont, Aimery

Publikováno v: Cancer Medicine
Cancer Medicine, Wiley, 2016, 5 (4), pp.676-683. ⟨10.1002/cam4.635⟩
Cancer Medicine, 2016, 5 (4), pp.676-683. ⟨10.1002/cam4.635⟩

International audience; A multicenter, open-label, noncomparative, randomized phase II study (PEPCOL) was conducted to evaluate the efficacy and safety of the irinotecan or PEP02 (MM-398, nanoliposomal irinotecan) with leucovorin (LV)/5-fluorouracil

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::51981efb76f91eaa5053ce094baccf39
https://hal.sorbonne-universite.fr/hal-01312777

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer.

Autor: Chibaudel B; Department of Medical Oncology, Franco-British Institute, Levallois-Perret, France.; Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR), Paris, France.; Preclinical and Translational Cancer Research Unit, AAREC Filia Research (AFR), Paris, France., Maindrault-Gœbel F; Department of Medical Oncology, Saint-Antoine Hospital, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France., Bachet JB; Department of Gastroenterology, La Pitié-Salpetrière Hospital, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France., Louvet C; Department of Medical Oncology, Montsouris Mutualiste Institute, Paris, France., Khalil A; Department of Medical Oncology, Tenon Hospital, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France., Dupuis O; Department of Medical Oncology, Victor Hugo Clinic, Le Mans, France., Hammel P; Department of Gastroenterology, Beaujon Hospital, Assistance Publique des Hôpitaux de Paris (APHP), Clichy, France., Garcia ML; Department of Medical Oncology, Saint-Antoine Hospital, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France., Bennamoun M; Department of Medical Oncology, Montsouris Mutualiste Institute, Paris, France., Brusquant D; Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR), Paris, France., Tournigand C; Department of Medical Oncology, Henri Mondor Hospital, Créteil, France., André T; Department of Medical Oncology, Saint-Antoine Hospital, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France., Arbaud C; Methodological and quality of life unit in oncology (EA3181) & Quality of life and cancer clinical research platform, CHU Besançon, Besançon, France., Larsen AK; Cancer Biology and Therapeutics, INSERM U938 and Pierre and Marie Curie University, Paris, France., Wang YW; PharmaEngine, Inc., Taipei, Taiwan., Yeh CG; PharmaEngine, Inc., Taipei, Taiwan., Bonnetain F; Methodological and quality of life unit in oncology (EA3181) & Quality of life and cancer clinical research platform, CHU Besançon, Besançon, France., de Gramont A; Department of Medical Oncology, Franco-British Institute, Levallois-Perret, France.

Publikováno v: Cancer medicine [Cancer Med] 2016 Apr; Vol. 5 (4), pp. 676-83. Date of Electronic Publication: 2016 Jan 24.